Acta Med. 2020, 63: 1-9

https://doi.org/10.14712/18059694.2020.9

Melanoma Incidence in Czech Republic, the Relation between Histology, Body Site of Melanoma, and Duration of Lesions

Jarmila Čelakovskáa, Josef Bukačb, Lenka Čákováa, Marie Šimkováa, Eva Jandováa

aDepartment of Dermatology and Venereology Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, Czech Republic
bDepartment of Medical Biophysics, Medical Faculty of Charles University, Hradec Králové, Czech Republic

Received September 30, 2019
Accepted November 29, 2019

References

1. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Investig Dermatol 2009; 129(7): 1666–74. <https://doi.org/10.1038/jid.2008.423> <PubMed>
2. Surveillance, Epidemiology, and End Results (SEER). Program Cancer Statistics Review, 1975–2013, National Cancer Institute [Internet] Nov, 2015. SEER data submission [cited posted to the SEER web site, 2016 Apr]. Available from: http://seer.cancer.gov/csr/1975_2013/.
3. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Exp Rev Anticancer Ther 2010; 10(11): 1811–23. <https://doi.org/10.1586/era.10.170> <PubMed>
4. Australian Bureau of Statistics. (2012). 3303.0. – Causes of death, Australia 2010: Underlying causes of death. (Excel spreadsheet). Canberra, Australia: ABS. Retrieved from www.abs.gov.au/AUSSTATS /abs@.nsf/DetailsPage/3303.02010.
5. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2013. Available from: http://globocan.iarc.fr.
6. Cancer Council ACT. (2017). Skin cancer in Australia. Available from: www.actcancer.org/prevention/sunsmart/skin-cancer-in-Australia.
7. Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC. Vital signs: Melanoma incidence and mortality trends and projections – United States, 1982–2030. MMWR Morb Mortal Wkly Rep 2015; 64(21): 591–6.
8. Califano J, Nance M. Malignant melanoma. Facial Plast Surg Clin North Am 2009; 17(3): 337–48. <https://doi.org/10.1016/j.fsc.2009.05.002>
9. Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P. Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol 2016; 120(1): 1–12. <https://doi.org/10.1016/j.radonc.2016.06.003>
10. Goodson AG, Grossman D. Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol 2009; 60(5): 719–35. quiz 36–8. <https://doi.org/10.1016/j.jaad.2008.10.065> <PubMed>
11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67(1): 7–30. <https://doi.org/10.3322/caac.21387>
12. Koh HK, Geller AC, Miller DR, Grossbart TA, Lew, RA. Prevention and early detection strategies for melanoma and skin cancer. Current status Arch Dermatol 1996; 132(4): 436–43. <https://doi.org/10.1001/archderm.1996.03890280098014>
13. Armstrong BK, Cust AE. Sun exposure and skin cancer, and the puzzle of cutaneous melanoma: a perspective on Fears et al. mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. Cancer Epidemiol 2017; 48: 147–56. <https://doi.org/10.1016/j.canep.2017.04.004>
14. D’Orazio J, Jarrett S, Amaro-Ortiz A, Scott T. UV radiation and the skin. Int J Mol Sci 2013; 14(6): 12222–48. <https://doi.org/10.3390/ijms140612222> <PubMed>
15. Colantonio S, Bracken MB, Beecker, J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol 2014; 70(5): 847–57. e1–18. <https://doi.org/10.1016/j.jaad.2013.11.050>
16. Pawlak MT, Bui M, Amir M, Burkhardt DL, Chen AK, Dellavalle RP. Legislation restricting access to indoor tanning throughout the world. Arch Dermatol 2012; 148(9): 1006–12. <https://doi.org/10.1001/archdermatol.2012.2080>
17. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139(12): 1620–4. <https://doi.org/10.1001/archderm.139.12.1620>
18. Haenssle HA, Mograby N, Ngassa, A, et al. Association of patient risk factors and frequency of nevus-associated cutaneous melanomas. JAMA Dermatol 2016; 152(3): 291–8. <https://doi.org/10.1001/jamadermatol.2015.3775>
19. Moher D, Hopewell S, Schulz KF, et al. For the CONSORT Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trial. BMJ 2010; 340: 869. <https://doi.org/10.1136/bmj.c869> <PubMed>
20. Berg SA, Ming ME. Recent Advances in Our Understanding of the Epidemiology of Melanoma. Curr Derm Rep 2017; 6(3): 211–21. <https://doi.org/10.1007/s13671-017-0193-6>
21. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 2007; 60: 32–40. <https://doi.org/10.1016/j.bjps.2006.05.008>
22. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3–9. <https://doi.org/10.1016/j.clindermatol.2008.09.001>
23. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331: 481. <https://doi.org/10.1136/bmj.38516.649537.E0> <PubMed>
24. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 1999; 135: 275–80.
25. Hall HI, Jamison P, Fulton JP, Clutter G, Roffers S, Parrish P. Reporting cutaneous melanoma to cancer registries in the United States. J Am Acad Dermatol 2003; 49: 624–30. <https://doi.org/10.1067/S0190-9622(03)00885-5>
26. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol 2011; 65(5 suppl 1): S17–S25, e1–3. <https://doi.org/10.1016/j.jaad.2011.04.032>
27. Mounessa, JS, Caravaglio JV, Dellavalle RP. Comparison of regional and state differences in melanoma rates in the United States: 2003 vs 2013. JAMA Dermatol 2017; 153: 345–7. <https://doi.org/10.1001/jamadermatol.2016.4625>
28. Cockburn M, Swetter SM, Peng D, Keegan TH, Deapen D, Clarke CA. Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol 2008; 59: 1081–5. <https://doi.org/10.1016/j.jaad.2008.08.007> <PubMed>
29. Watson M, Johnson CJ, Chen VW, et al. Melanoma surveillance in the United States: overview of methods. J Am Acad Dermatol 2011; 65(5 suppl 1): S6–S16. <https://doi.org/10.1016/j.jaad.2011.04.037>
30. Shaikh WR, Weinstock MA, Halpern AC, Oliveria SA, Geller AC, Dusza SW. The characterization and potential impact of melanoma cases with unknown thickness in the United States’ Surveillance, Epidemiology, and End Results Program, 1989–2008. Cancer Epidemiol 2013; 37: 64–70. <https://doi.org/10.1016/j.canep.2012.08.010>
31. Gimotty PA, Shore R, Lozon NL, et al. Miscoding of melanoma thickness in SEER: research and clinical implications. J Invest Dermatol 2016; 136: 2168–72. <https://doi.org/10.1016/j.jid.2016.05.121> <PubMed>
32. Rastrelli M, Tropea S, Rossi C, Alaibac M. Melanoma, Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification. In vivo 2014; 28(6): 1005–11.
33. Johnson-Obaseki S, Labajian V, Corsten MJ, McDonald, J. Incidence of cutaneous malignant melanoma by socioeconomic status in Canada: 1992–2006. J Otolaryngol Head Neck Surg 2015; 44: 53. <https://doi.org/10.1186/s40463-015-0107-1> <PubMed>
34. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2017. CA Cancer J Clin 2017; 67(1): 7–30. <https://doi.org/10.3322/caac.21387>
35. Liu F, Bessonova L, Taylor TH, Ziogas A, Meyskens FL Jr, Anton-Culver H. A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res 2013; 26(1): 128–35. <https://doi.org/10.1111/pcmr.12035> <PubMed>
36. Liu-Smith F, Farhat AM, Arce A, et al. Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure. J Am Acad Dermatol 2017; 76(3): 499–505, e3. <https://doi.org/10.1016/j.jaad.2016.08.027> <PubMed>
37. Liu-Smith F, Ziogas A. An age-dependent interaction between sex and geographical UV index in melanoma risk. J Am Acad Dermatol 2017, pii: S0190-9622(17)32748-2.
38. Howlader, N, Noone, AM, Krapcho M (eds). SEER cancer statistics review, 1975–2014, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
39. Joosse A, Collette S, Suciu S, et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol 2013; 31(18): 2337–46. <https://doi.org/10.1200/JCO.2012.44.5031>
40. Courtenay WH. Constructions of masculinity and their influence on men’s well-being: a theory of gender and health. Soc Sci Med 2000; 50(10): 1385–40. <https://doi.org/10.1016/S0277-9536(99)00390-1>
41. Stanton WR, Janda M, Baade PD, Anderson P. Primary prevention of skin cancer: A review of sun protection in Australia and internationally. Health Promotion International 2004; 19(3): 369–78. <https://doi.org/10.1093/heapro/dah310>
42. Hillhouse J, Turrisi R, Stapleton J, Robinson J. A randomized controlled trial of an appearance‐focused intervention to prevent skin cancer. Cancer 2008; 113(11): 3059–274. <https://doi.org/10.1002/cncr.23922> <PubMed>
43. Jackson K, Aiken L. A psychosocial model of sun protection and sunbathing in young women: The impact of health beliefs, attitudes, norms and self‐efficacy for sun protection. Health Psychology 2000; 19(5): 469–78. <https://doi.org/10.1037/0278-6133.19.5.469>
44. Ghiasvand R, Robsahm TE, Green AC, et al. Association of Phenotypic Characteristics and UV Radiation Exposure With Risk of Melanoma on Different Body Sites. JAMA Dermatol 2019; 155(1): 39–49. <https://doi.org/10.1001/jamadermatol.2018.3964> <PubMed>
45. Pérez-Gómez B, Aragonés N, Gustavsson P, Lope V, López-Abente G, Pollán M. Do sex and site matter? Different age distribution in melanoma of the trunk among Swedish men and women. Br J Dermatol 2008; 158(4): 766–72. <https://doi.org/10.1111/j.1365-2133.2007.08429.x>
46. Bevona C, Fewkes J, Liu V, Sober AJ. Prolonged evolution of a lentigo maligna. J Am Acad Dermatol 2004; 51(5): 830–5. <https://doi.org/10.1016/j.jaad.2002.09.002>
47. Haenssle HA, Mograby N, Ngassa A, et al. Association of patient risk factors and frequency of nevus-associated cutaneous melanomas. JAMA Dermatol 2016; 152(3): 291–8. <https://doi.org/10.1001/jamadermatol.2015.3775>
48. Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green AC. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006; 24(19): 3172–7. <https://doi.org/10.1200/JCO.2006.06.1325>
49. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24(5): 879–97. <https://doi.org/10.1111/j.1755-148X.2011.00880.x> <PubMed>
50. Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer 2016; 16(6): 345–58. <https://doi.org/10.1038/nrc.2016.37>
51. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41: 28–44. <https://doi.org/10.1016/j.ejca.2004.10.015>
52. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41: 45–60. <https://doi.org/10.1016/j.ejca.2004.10.016>
53. Caini S, Gandini S, Sera F, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clino-pathological variant. Eur J Cancer 2009; 45: 3054–63. <https://doi.org/10.1016/j.ejca.2009.05.009>
54. Olsen CM, Zens MS, Green AC, et al. Biologic markers of sun exposure and melanoma risk in women: pooled case-control analysis. Int J Cancer 2011; 129: 713–23. <https://doi.org/10.1002/ijc.25691> <PubMed>
55. Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol 2005; 141(6): 745–50.
56. Lino-Silva LS, Dominguez-Rodriguez JA, Aguilar-Romero JM, et al. Melanoma in Mexico: clinicopathologic features in a population with predominance of acral lentiginous subtype. Ann Surg Oncol 2016; 23(13): 4189–94. <https://doi.org/10.1245/s10434-016-5394-x>
57. Dal H, Boldemann C, Lindelöf B. Does relative melanoma distribution by body site 1960–2004 reflect changes in intermittent exposure and intentional tanning in the Swedish population? Eur J Dermatol 2007; 17(5): 428–34.
58. Watts CG, Madronio C, Morton RL, et al. Clinical features associated with individuals at higher risk of melanoma: a population-based study. JAMA Dermatol 2017; 153(1): 23–9. <https://doi.org/10.1001/jamadermatol.2016.3327>
59. Barysch MJ, Levesque MP, Cheng P, et al. Coexpression of SOX10/ CD271 (p75(NTR)) and beta-galactosidase in large to giant congenital melanocytic nevi of pediatric patients. Dermatopathology (Basel) 2014; 1(1): 35–46. <https://doi.org/10.1159/000362490> <PubMed>
60. Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006; 155(1): 1–8. <https://doi.org/10.1111/j.1365-2133.2006.07218.x>
61. van der Leest R, Flohil S, Arends L, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015; 29(6): 1053–62. <https://doi.org/10.1111/jdv.12887>
62. Kubica A, Brewer J. Melanoma in immunosuppressed patients. Mayo Clin Proc 2012; 87(10): 991–1003. <https://doi.org/10.1016/j.mayocp.2012.04.018> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Archive